Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Picankibart - Innovent Biologics

Next Previous
Drug Profile

Picankibart - Innovent Biologics

Alternative Names: Anti-interleukin 23p19 subunit antibody injection - Innovent Biologics; IBI-112

Latest Information Update: 02 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovent Biologics
  • Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action Interleukin-23 subunit p19 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Plaque psoriasis
  • Phase II Ulcerative colitis
  • Discontinued Gastrointestinal disorders

Most Recent Events

  • 28 May 2025 Phase-III clinical trials in Plaque psoriasis (Treatment-experienced) in China (SC) (NCT06945107)
  • 29 Apr 2025 Innovent Biopharmaceutical Technology plans a phase III trial for Plaque psoriasis (Treatment-experience) in China in May 2025 (SC) (NCT06945107)
  • 26 Jan 2025 Innovent Biologics completes phase-II clinical trials in Plaque psoriasis (Treatment-experienced) in China (SC) (NCT05970978)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top